2025-02-27 DIGITIMES ASIA HaiPress
TAIPEI,Feb. 26,2025 -- According to the news report from the technology-focused mediaDIGITIMES Asia,Huawei's Ascend 910C AI chip has reportedly reached a 40% manufacturing yield,marking the first time the Ascend production line has turned profitable. The company aims to improve the yield to 60%,bringing it closer to industry standards.
Credit: DIGITIMES
Yield improvement and profitability milestone
TheFinancial Times,citing industry sources,reports that Huawei's Ascend 910C,manufactured using the SMIC 7nm (N+2) process,has improved its yield rate to nearly 40%,making the Ascend production line profitable for the first time.
Production targets for 2025
Huawei plans to produce 100,000 Ascend 910C chips and 300,000 Ascend 910B chips in 2025—up from zero and 200,000 units in 2024,respectively. The company now accounts for over 75% of China's total AI chip production,highlighting its growing presence in the domestic semiconductor market.
Yield gains and sector benchmark
In September 2024,reports fromReuters,Yahoo Finance,andTrendForcerevealed that Ascend 910C's yield was only 20%,while the older Ascend 910B reached 50%. Since then,Huawei has doubled the 910C's yield,aiming for 60% to match industry norms.
Performance comparison with Nvidia
According toICSmartandTom's Hardware,Huawei's Ascend 910C delivers 60% of the inference performance of Nvidia's H100 GPU. While it still trails Nvidia's next-generation Blackwell AI chips,its advancement signals China's push to reduce reliance on Nvidia's hardware.
Shift to domestic foundry amid US sanctions
Due to US trade restrictions,TSMC halted production of Huawei's AI chips in 2020. Huawei has since shifted manufacturing to SMIC,ensuring continued chip production despite sanctions.
Analysts view Huawei's progress with the Ascend 910C as a key milestone in China's push for semiconductor self-sufficiency,reducing its dependence on Western chipmakers.
Jewellery & Gem ASEAN Bangkok (JGAB) 2025: Connecting ASEAN's Gem and Jewellery Business to the Global Market
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
Acer Reports FY2024 Net Income of NT$5.54 Billion and NT$1.7 Cash Dividend Per Share
Ping An #1 in Brand Finance's Global Insurance Brand Value for 9th Year, Brand Value Reaches $33.6 Billion
LITEON Showcase Groundbreaking Energy Savings in Private 5G Network with NTT EAST at MWC 2025
2025 Global Sources Hong Kong Shows: Shaping the Future of Consumer Trends and Redefining Sourcing
©copyright 2009-2020 Singapore Info Map